Agenus Inc.

01/23/2025 | Press release | Distributed by Public on 01/23/2025 13:54

TPS 515: A phase II study of agenT 797 (invariant natural killer T cells), botensilimab (Fc enhanced CTLA 4 inhibitor) and balstilimab (anti PD 1) in patients with advanced,[...]